UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.16
−2.64%Aug 12, 2026, 00:00 UTC
Unicycive Therapeutics reported its Q2 2026 financial results, with a net loss of $1.7 million and diluted EPS of -$0.06, compared to a net loss of $6.5 million in Q2 2025.
Jun 30, 2026, 16:51 UTC
The FDA issued a second Complete Response Letter to Unicycive Therapeutics regarding the resubmitted OLC NDA, citing the same third-party manufacturing deficiencies as in the prior CRL.